Enzene wins CPHI manufacturing excellence award

FRANKFURT, Germany – October 29, 2025 – Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), today welcomed the news that its EnzeneX™ 2.0 platform, featuring fully-connected continuous manufacturing™ (FCCM™) technology, won the 2025 CPHI Pharma Award for Manufacturing Excellence.

The award recognizes innovation in technologies, processes, and services for the manufacture of various dose forms, and as the first truly fully-connected continuous manufacturing technology to be validated for commercial biologics supply, the award acknowledged the EnzeneX 2.0 platform for advancing bioprocessing.

“I am delighted to accept this award on behalf of Enzene,” commented Himanshu Gadgil, Ph.D., CEO of Enzene. “By taking advantage of the modular design of the EnzeneX platform, and its integrated process controls, innovators have not only validated the FCCM technology for commercial-scale supply, but have also successfully driven down the costs of bioprocessing, across a broad range of biologic modalities.”

The Enzene platform was one of four finalists selected by a panel of pharma industry experts. The winner’s award was presented to Enzene at a ceremony on October 28, 2025 at CPHI Frankfurt, the world’s largest pharmaceutical event, which is currently taking place at Messe Frankfurt.

About Enzene
We Are Enzene, a Continuously Innovative Development and Manufacturing (CIDMO) partner to innovators and biosimilar developers. From state-of-the-art sites in Pune, India, and Hopewell, New Jersey, we provide fully-integrated services that span discovery, development, and commercial supply.

Our innovative EnzeneX™ platform incorporates the first truly fully-connected continuous manufacturing™ (FCCM™) technology to be validated for commercial biologics supply. We are proud pioneers of next-generation biologics technologies, and disruptors of existing biologics manufacturing paradigms: accelerating time-to-market and providing the highest production yields to drive down the cost of a broad range of biologic modalities.

For more information on Enzene, please visit www.enzene.com